ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "dendritic cells and tofacitnib"

  • Abstract Number: 726 • 2013 ACR/ARHP Annual Meeting

    Tofacitinib Does Not Inhibit Dendritic Cell Maturation and T Cell Proliferation In Vitro

    Emmanuelle Le Bras1,2, Dagmar Halbritter3 and Martin Fleck2,4, 1Internal Medicine I, University Medical Center of Regensburg, Regensburg 93053, Germany, 2Rheumatology & Clinical Immunology, Asklepios Clinic Bad Abbach, Bad Abbach, Germany, 3Internal Medicine I, University Medical Center of Regensburg, 93042 Regensburg, Germany, 4Internal Medicine I, University Medical Center of Regensburg, Regensburg, Germany

    Background/Purpose: Tofacitinib is the first approved Janus Kinase (JAK) Inhibitor for the treatment of rheumatoid arthritis (RA). The JAK/STAT pathway-inhibition leads to dysfunction of several…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies